Abstract
Purpose
This study seeks to assess the differences in disease and socioeconomic characteristics, late effects and long-term quality of life (QoL) after head-and-neck cancer (HNC) among participants and non-participants.
Methods
Five hundred sixty recurrence-free survivors treated for HNC at least 6 months previously were invited to participate in a repeated measure, controlled intervention study of computerized Patient Reported Outcome (PRO), which is provided to treating physicians at the point of care. Two hundred sixty-six consented to participate, and 292 declined; of those who declined, 103 filled in the baseline questionnaire. Late effects and QoL were evaluated on the EORTC QLQ C-30 and EORTC QLQ H&N35 and HADS questionnaires, and an empirically derived symptom list was prepared with hospital clinicians.
Results
Participants were younger, had a higher educational level, were more likely to cohabit, less likely to smoke, used less alcohol and were more likely to have HPV than those who declined but did not differ by gender, cancer site, stage or time since diagnosis. Participants reported significantly better QoL and functioning and less severe symptoms than those who declined participation other than filling in the baseline questionnaire.
Conclusions
Late symptoms are common in HNC survivors. A wide diversity of self-reported late effects was found in this trial with participants significantly less affected than non-participants.
Implications for Cancer Survivors
Generalizable data on non-participation may aid in the interpretation of studies on HNC survivors in general and may have relevance for targeting recruitment and maintenance in rehabilitation and follow-up care, outside clinical trials.
Similar content being viewed by others
References
Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770–6.
Payakachat N, Ounpraseuth S, Suen JY. Late complications and long-term quality of life for survivors (>5 years) with history of head and neck cancer. Head Neck. 2013;35:819–25.
Cartmill B, Cornwell P, Ward E, Davidson W, Porceddu S. Long-term functional outcomes and patient perspective following altered fractionation radiotherapy with concomitant boost for oropharyngeal cancer. Dysphagia. 2012;27:481–90.
Funk GF, Karnell LH, Christensen AJ. Long-term health-related quality of life in survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2012;138:123–33.
Mortensen HR, Overgaard J, Specht L, Overgaard M, Johansen J, Evensen JF, et al. Prevalence and peak incidence of acute and late normal tissue morbidity in the DAHANCA 6&7 randomised trial with accelerated radiotherapy for head and neck cancer. Radiother Oncol. 2012;103:69–75.
De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol Head Neck Surg. 1999;120:427–36.
Bjordal K, Kaasa S. Psychological distress in head and neck cancer patients 7–11 years after curative treatment. Br J Cancer. 1995;71:592–7.
Chen AM, Daly ME, Vazquez E, Courquin J, Luu Q, Donald PJ, et al. Depression among long-term survivors of head and neck cancer treated with radiation therapy. JAMA Otolaryngol Head Neck Surg. 2013;139:885–9.
Ghazali N, Cadwallader E, Lowe D, Humphris G, Ozakinci G, Rogers SN. Fear of recurrence among head and neck cancer survivors: longitudinal trends. Psychooncology. 2013;22:807–13.
Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624–32.
Jensen K, Lambertsen K, Torkov P, Dahl M, Jensen AB, Grau C. Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol. 2007;46:1159–68.
Sollner W, Devries A, Steixner E, Lukas P, Sprinzl G, Rumpold G, et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling? Br J Cancer. 2001;84:179–85.
Luckett T, Butow PN, King MT. Improving patient outcomes through the routine use of patient-reported data in cancer clinics: future directions. Psychooncology. 2009;18:1129–38.
Mark TL, Fortner B, Johnson G. Evaluation of a tablet PC technology to screen and educate oncology patients. Support Care Cancer. 2008;16:371–8.
Ruland CM, Holte HH, Roislien J, Heaven C, Hamilton GA, Kristiansen J, et al. Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients’ need for symptom management support: a randomized clinical trial. J Am Med Inform Assoc. 2010;17:403–10.
Kotronoulas G, Kearney N, Maguire R, Harrow A, Di DD, Croy S, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32:1480–501.
Gourin CG, Kaboli KC, Boyce BJ, Burkhead LM. Factors associated with nonparticipation in one-year quality-of-life assessment in patients with head and neck squamous cell carcinoma. Laryngoscope. 2010;120:1435–43.
Kaur G, Hutchison I, Mehanna H, Williamson P, Shaw R, Tudur SC. Barriers to recruitment for surgical trials in head and neck oncology: a survey of trial investigators. BMJ Open. 2013;3.
Fayers PM. Evaluating the effectiveness of using PROs in clinical practice: a role for cluster-randomised trials. Qual Life Res. 2008;17:1315–21.
Ruland CM, Andersen T, Jeneson A, Moore S, Grimsbo GH, Borosund E, et al. Effects of an internet support system to assist cancer patients in reducing symptom distress: a randomized controlled trial. Cancer Nurs. 2013;36:6–17.
Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;15(22):714–24.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;3(85):365–76.
DAHANCA. www.dahanca.dk. Assessed April 2014.
Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112:228–42.
Howerton MW, Gibbons MC, Baffi CR, Gary TL, Lai GY, Bolen S, et al. Provider roles in the recruitment of underrepresented populations to cancer clinical trials. Cancer. 2007;109:465–76.
Baquet CR, Mack KM, Bramble J, Deshields M, Datcher D, Savoy M, et al. Maryland’s Special Populations Cancer Network: cancer health disparities reduction model. J Health Care Poor Underserved. 2005;16:192–206.
Go RS, Frisby KA, Lee JA, Mathiason MA, Meyer CM, Ostern JL, et al. Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer. 2006;15(106):426–33.
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;9(291):2720–6.
Movsas B, Moughan J, Owen J, Coia LR, Zelefsky MJ, Hanks G, et al. Who enrolls onto clinical oncology trials? A radiation Patterns Of Care Study analysis. Int J Radiat Oncol Biol Phys. 2007;15(68):1145–50.
Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, et al. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013;31:536–42.
Colangelo LA, Logemann JA, Rademaker AW, Pauloski BR, Smith CH, McConnel FM, et al. Factors related to dropout in a study of head and neck cancer patients after surgery. Otolaryngol Head Neck Surg. 1999;120:368–74.
Fang FM, Tsai WL, Chien CY, Chiu HC, Wang CJ, Chen HC, et al. Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation. Oncology. 2005;68:405–13.
Monson K, Parlour L, Simcock R, Fallowfield L, Jenkins V. Group recruitment sessions enhance patient understanding in a small multi-centre phase III clinical trial. Contemp Clin Trials. 2012;33:286–90.
Chaukar DA, Walvekar RR, Das AK, Deshpande MS, Pai PS, Chaturvedi P, et al. Quality of life in head and neck cancer survivors: a cross-sectional survey. Am J Otolaryngol. 2009;30:176–80.
Thomas L, Moore EJ, Olsen KD, Kasperbauer JL. Long-term quality of life in young adults treated for oral cavity squamous cell cancer. Ann Otol Rhinol Laryngol. 2012;121:395–401.
Llewellyn CD, McGurk M, Weinman J. Are psycho-social and behavioural factors related to health related-quality of life in patients with head and neck cancer? A systematic review. Oral Oncol. 2005;41:440–54.
Burkett VS, Cleeland CS. Symptom burden in cancer survivorship. J Cancer Surviv. 2007;1:167–75.
So WK, Chan RJ, Chan DN, Hughes BG, Chair SY, Choi KC, et al. Quality-of-life among head and neck cancer survivors at one year after treatment—a systematic review. Eur J Cancer. 2012;48:2391–408.
Hollen PJ, Gralla RJ, Stewart JA, Meharchand JM, Wierzbicki R, Leighl N. Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL). Support Care Cancer. 2013;21:165–72.
Research support
This study was supported by the Danish Cancer Society (number R17-A744), The Health Foundation (number 2010B043), and The Danish Agency for Science, Technology and Innovation (number 10-078272).
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kjaer, T., Johansen, C., Andersen, E. et al. Do we reach the patients with the most problems? Baseline data from the WebCan study among survivors of head-and-neck cancer, Denmark. J Cancer Surviv 10, 251–260 (2016). https://doi.org/10.1007/s11764-015-0471-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11764-015-0471-x